IL-10 can have favorable or unfavorable effects in SLE because of its pleomorphic properties; however, a favorable phase I safety trial of an anti-IL-10 (Schering, Berlin, Germany) is not likely to lead to further development because of its numerous contradictory actions. Here, IL10 is linked to systemic lupus erythematosus.